- 1 Identification of *de novo* mutations in prenatal neurodevelopment-associated genes in
- 2 schizophrenia in two Han Chinese patient-sibling family-based cohorts
- 3 Running head: Identification of *de novo* mutations in schizophrenia in Chinese families
- 4 Shan Jiang^{1,*}, Daizhan Zhou^{2,3,*}, Yin-Ying Wang¹, Peilin Jia¹, Chunling Wan^{2,3}, Xingwang Li^{2,3},
- 5 Guang He^{2,3}, Dongmei Cao², Xiaoqian Jiang⁴, Kenneth S. Kendler⁵, Ming Tsuang⁶, Travis
- 6 Mize^{7,8}, Jain-Shing Wu⁹, Yimei Lu⁹, Lin He^{2,3,10,#}, Jingchun Chen^{9,#}, Zhongming Zhao^{1,11,12,#} and
- 7 Xiangning Chen^{13,#}
- ¹Center for Precision Health, School of Biomedical Informatics, The University of Texas Health
- 9 Science Center at Houston, Houston, TX 77030, USA.
- ²Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric
- Disorders (Ministry of Education), Collaborative Innovation Center for Brain Science, Shanghai
- 12 Jiao Tong University, Shanghai, China.
- ³Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai
- 14 Jiao Tong University School of Medicine, Shanghai, China.
- ⁴School of Biomedical Informatics, The University of Texas Health Science Center at Houston,
- 16 Houston, TX 77030, USA.
- ⁵Virginia Institute of Psychiatric and Behavioral Genetics, Medical College of Virginia and
- 18 Virginia Commonwealth University, Richmond, VA, 23298, USA.
- ⁶Department of Psychiatry, University of California at San Diego, San Diego, CA, 92093, USA.
- Department of Ecology and Evolutionary Biology, University of Colorado Boulder, Boulder,
- 21 CO 80309, USA.

- ⁸Institute for Behavioral Genetics, University of Colorado Boulder, Boulder, CO 80309, USA.
- ⁹Nevada Institute of Personalized Medicine, University of Nevada Las Vegas, Las Vegas, NV
- 24 89154, USA.
- 25 ¹⁰Institute of Neuropsychiatric Science and Systems Biological Medicine, Shanghai Jiao Tong
- 26 University, Shanghai, China.
- 27 ¹¹MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston,
- 28 TX 77030, USA.

- ¹²Human Genetics Center, School of Public Health, The University of Texas Health Science
- 30 Center at Houston, Houston, TX 77030, USA.
- 31 ¹³410 AI, LLC, Germantown, MD 20876, USA.
- *These authors contributed equally.
- [#]Correspondence: Lin He (<u>helin@bio-x.cn</u>) or Jingchun Chen (<u>Jingchun.chen@unlv.edu</u>) or
- 35 Zhongming Zhao (Zhongming.Zhao@uth.tmc.edu) or Xiangning Chen
- 36 (va.samchen@gmail.com).

Abstract

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

Schizophrenia (SCZ) is a severe psychiatric disorder with a strong genetic component. High heritability of SCZ suggests a major role for transmitted genetic variants. Furthermore, SCZ is also associated with a marked reduction in fecundity, leading to the hypothesis that alleles with large effects on risk might often occur de novo. In this study, we conducted whole-genome sequencing for 23 families from two cohorts with matched unaffected siblings and parents. Two nonsense de novo mutations (DNMs) in GJC1 and HIST1H2AD were identified in SCZ patients. Ten genes (DPYSL2, NBPF1, SDK1, ZNF595, ZNF718, GCNT2, SNX9, AACS, KCNQ1 and MSI2) were found to carry more DNMs in SCZ patients than their unaffected siblings by burden test. Expression analyses indicated that these DNM implicated genes showed significantly higher expression in prefrontal cortex in prenatal stage. The DNM in the GJC1 gene is highly likely a loss function mutation (pLI = 0.94), leading to the dysregulation of ion channel in the glutamatergic excitatory neurons. Analysis of rare variants in independent exome sequencing dataset indicates that GJC1 has significantly more rare variants in SCZ patients than in unaffected controls. Data from genome-wide association studies suggested that common variants in the GJC1 gene may be associated with SCZ and SCZ-related traits. Genes co-expressed with GJC1 are involved in SCZ, SCZ-associated pathways and drug targets. These evidence suggest that GJC1 may be a risk gene for SCZ and its function may be involved in prenatal and early neurodevelopment, a vulnerable period for developmental disorders such as SCZ. **Key words**: schizophrenia, *de novo* mutation, whole genome sequencing, neurodevelopment, loss-of-function

Introduction

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

Schizophrenia (SCZ) is a severe psychiatric disorder that profoundly affects cognitive, behavior and emotional processes, yet its etiology and pathophysiology are still largely unknown. The high heritability of SCZ suggests that genetic risk factors contribute to a significant proportion of the etiology ^{1, 2}. However, the marked reduction in fecundity in SCZ patients suggests the removal of risk variants with the largest effects from the population by natural selection. Thus these variants often occur de novo. Indeed, the strongest genetic risk factors for SCZ identified so far are *de novo* large copy number variants (CNV)³. The availability of next-generation sequencing permits the detection of *de novo* mutation (DNM) events at the genome level. Through large-scale sequencing in parent-offspring trios, DNM have been increasingly discovered from an array of severe neurodevelopmental disorders, including Autism Spectrum Disorders (ASD) ⁴, Attention-Deficit Hyperactivity Disorder (ADHD) ⁵ and epileptic encephalopathy ⁶. For SCZ, Xu et al. showed a large excess of de novo nonsynonymous changes and DNMs presented with greater potential to affect protein structures and functions in SCZ patients ⁷; Girard *et al.* reported increased exonic DNM rate in SCZ patients ⁸; and Fromer et al. found that DNMs in SCZ implicated synaptic networks and DNM-affected genes in SCZ overlapped with those mutated in other neurodevelopmental disorders ⁹. Whole exome sequencing (WES) was applied predominantly in DNM identification thus far, however, few DNM studies have been based on whole genome sequencing (WGS) as WES remains a costeffective strategy. However, only 1.22% of DNMs are within exonic regions ¹⁰ and meaningful mutations may occur outside of exons, such as in regulatory elements (i.e. transcriptional promoters, enhancers and suppressors) thereby altering expression level of governed genes. Similarly, mutations

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

within exon-intron junction regions may influence splice sites and thus lead to inappropriate expression of particular isoforms ¹¹. Takata *et al.* reported that cis-acting splicing quantitative trait loci from prefrontal cortices of human were in linkage disequilibrium with SCZ genomewide association study (GWAS) loci and DNMs near splicing sites were enriched in SCZ patients as compared to controls ^{12, 13}. Emerging roles of non-coding RNAs such as microRNA, circRNA and lncRNA further call for attention to explore DNMs in non-coding regions. We therefore conducted WGS on two cohorts of Chinese families with matched patient-sibling to capture all classes of DNMs and to more fully describe the genetic architecture of SCZ. This study was conducted to identify potential DNMs in SCZ in the Asian population, adding to the growing body of information regarding ethnicity-specific DNMs. Methods Subjects Subjects were drawn from two distinct cohorts, Taiwan and Shanghai, of Han Chinese origin. Recruitment of subjects from the Taiwan cohort was described in previous publications ^{14, 15}. The rationale for combining the two cohorts was to increase the power to detect DNMs because each of the two cohorts has small sample size but they are ethnically homogeneous. Briefly, families with at least three siblings, two of whom were diagnosed with SCZ, were recruited in the Taiwan Schizophrenia Linkage Study (TSLS) from 1998 to 2002. All recruited subjects were interviewed using the Diagnostic Interview for Genetic Studies (DIGS) ¹⁶, accompanied with the Family Diagnostic Interview for Genetic Studies (FIGS) (https://www.nimhgenetics.org/resources/clinical-instruments/figs/list-of-figs). Final diagnostic assessment was based on the criteria of the fourth edition of the Diagnostic and Statistical

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

Manual (DSM-IV), joined with the record of DIGS, FIGS, interviewer notes, and hospital anamnesis. For the Shanghai cohort, families from the Bio-x SCZ Biobank with at least three siblings, two of whom were diagnosed with SCZ, were selected. All families from the Bio-x SCZ Biobank were recruited from the city of Shanghai and the provinces of Hebei, Liaoning and Guangxi from 2001 to 2003. All individuals with SCZ were interviewed by two independent psychiatrists and diagnosed according to DSM-IV criteria. A total of 23 families (10 from Taiwan and 13 from Shanghai), with SCZ patients, matched unaffected siblings and parents, were used in this study (Figure 1). For detailed demographic characteristics of all individuals in the 23 families, please refer to Supplementary Table S1. All subjects gave written informed consent with the approval of the local research ethics committees. Whole genome sequencing For the subjects of Taiwan cohort, whole blood samples were collected with anticoagulant (EDTA) tubes and sent to the National Institute of Mental Health (NIMH) Repository and Genomics Resource (RGR). Lymphocytes from the whole blood samples were transformed into immortalized lymphoblastoid cell lines and stored. The DNA samples extracted from the cell lines were used for WGS. WGS was carried out on the Illumina HiSeq 2000 platform using paired-end chemistry with 75 base-pair read length through NovoGene, Inc. (Beijing, China). For detailed description please refer to previous publication ¹⁷. WGS data for the subjects of Taiwan cohort can be accessed in BioProject of NCBI: https://www.ncbi.nlm.nih.gov/bioproject/PRJNA551447. For the subjects from Shanghai cohort, whole blood samples were also collected with anticoagulant tubes. DNA was extracted from blood lymphocytes by standard procedures using FlexiGene DNA kits (Fuji, Tokyo, Japan). DNA libraries were prepared using protocols recommended by Illumina (Illumina, San Diego,

CA). WGS was performed on Illumina HiSeq-X Ten platform with 150 base-pair read length through Cloud Health Genomics Ltd. (Shanghai, China). Quality control and variant calling FastQC (v0.11.8) was used to perform quality checks on all samples across Taiwan and Shanghai cohorts (Supplementary Figure S1). The GATK best practices of variant calling were applied to process all raw reads from both Taiwan and Shanghai cohorts ¹⁸. Raw sequencing reads in FASTQ format were aligned to the GRCh37 build of the human reference genome with BWA-mem ¹⁹. Then the aligned reads in BAM format were sorted, indexed and marked with duplicate reads with Picard Tools. Reads containing indels were realigned with GATK's IndelRealigner tool. Next, GATK was used to perform Base Quality Score Recalibration (BQSR). Quality control after alignment was performed using Picard (v2.20.4) CollectAlignmentSummaryMetrics (Supplementary Table S2). Variant calling was performed across all samples with GATK (v4.1.1.0) HaplotypeCaller. For detailed variant calling pipeline, please refer to Supplementary Figure S2. To further systematically remove potentially false positively called variants, we applied the following quality filters for each variant: (1) the quality score normalized by allele depth is less than 2; (2) the root mean square of the mapping quality is less than 40; (3) the strand bias is more than 60; (4) three consecutive variants were clustered within 10 bases; and (5) the FILTER tag is not PASS.

Kinship analysis, DNM calling and annotation

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

We used PLINK to perform kinship analysis ²⁰. Briefly, for a given family, if the father was shown to be within the third degree relative to the mother, the family would be excluded; if the child was not shown to be the first degree relative to the parents, the child would be excluded. To ensure the DNM calls with high confidence, three tools, GATK PhyseByTransmission (PBT), TrioDeNovo (v0.0.6) and DeNovoGear (v.develop), were used to evaluate the calls ²¹⁻²³. Only DNMs called by all three tools consistently were considered as candidate DNMs. PBT was run with the following command: java – jar Genome Analysis TK. jar -T Phase By Transmission -R human g1k v37 decoy. fasta -V parent_child_trio.vcf -prior 1.0e-8 -mvf PBT_result.vcf TrioDeNovo was run with the following command: triodenovo --ped parent_child_pedigree.ped --in_vcf parent_child_trio.vcf --mu 1.0e-8 --out_vcf TrioDeNovo result.vcf DeNovoGear was run with the following command: dng dnm --ped parent_child_pedigree.ped -vcf parent_child_trio.vcf -s 1.0e-8 --write DeNovoGear_result.vcf After obtaining consistently called DNMs, the following five criteria were applied to retain high quality calls tagged with PASS in the FILTER annotation: (1) quality score is greater than or equal to 30; (2) genotypes of the parents are homozygotes; (3) genotype of the child is heterozygote; (4) phred-scaled maximum likelihood of heterozygote for the parents is less than 50; and (5) phred-scaled maximum likelihood of heterozygote of the child is 0. DNMs with MAF

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

greater than 0.01 in East Asian populations were further excluded by querying gnomAD (https://gnomad.broadinstitute.org/) and EXac (http://exac.broadinstitute.org/). Please refer to Supplementary Figure S2 for detailed pipeline of DNM calling and Supplementary Figure S3 for the distributions of DNM quality scores. Remaining DNMs were annotated using ANNOVAR ²⁴. Polymerase chain reaction (PCR)-based Sanger sequencing validation For the families where candidate DNMs were found, DNA from all members of the family was subjected to PCR-based Sanger sequencing by capillary electrophoresis according to standard molecular biology practices (ABI 3130 genetic analyzer, ThermoFisher Scientific). Primer3Plus was used to design the PCR primers ²⁵. For the *GJC1* mutation, the forward primer sequence was 5'-TTAGGTTTGGGTTGGCTCTG -3' and the reverse primer sequence was 5'-CACGGTGAAGCAGACAAGAA -3'. For the *HIST1H2AD* insertion, the forward primer sequence was 5'- CTCGTTTTACTTGCCCTTGG -3' and the reverse primer sequence was 5'-ACAACAAGAAGACCCGCATC -3'. Reactions were performed on an Eppendorf MasterCycler (Eppendorf North America, New York, USA) under the following cycling conditions: denaturation at 95 □ °C for 3 min, 35 cycles of $95\Box^{\circ}$ C for $15\Box$ sec, $55\Box^{\circ}$ C for 20 sec, 72 °C for 30 sec, and a final extension at 72 °C for 5 min. Sanger sequencing data was then analyzed using Chromas software (https://technelysium.com.au/wp/). Identification of genes implicated by coding DNMs in SCZ As the spontaneous background mutation rates vary greatly between genes, those carrying relatively more protein-coding DNMs in cases are not necessarily implicated by DNMs ²⁶. To identify those genes implicated by protein-coding DNMs or of which the DNMs occurred higher

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

than the background mutation rates, the R package denovolyzeR was used to analyze proteincoding DNMs based on a mutation model developed previously ²⁶. Briefly, denovolvzeR estimates underlying mutation rate based on trinucleotide context and incorporates exome depth and divergence adjustments based on macaque-human comparisons over a \pm 1-Mb window and accommodates known mutational biases, such as CpG hotspots. By applying the underlying mutation rate estimates, denovolyzeR generates prior probabilities for observing a specific number and class of mutations (synonymous, missense, nonsense, splice-site and frameshift) for a given gene. To validate whether the genes implicated by coding DNMs were also implicated by rare variants, the population-based SCZ Swedish case-control cohort with whole exome sequences and variants called were used to perform the analysis ²⁷. Variants with MAF greater than 0.01 were excluded and only rare variants were retained subsequently. The association between the set of rare variants from Swedish case-control cohort located in the exons of a given gene implicated by coding DNM and phenotype was tested using SKAT ²⁸. DNM burden test To determine whether some genes carry more DNMs in SCZ patients than expected by chance, we performed the DNM burden test for each gene potentially implicated by DNM. Human brainspecific gene enhancer information was included from PsychENCODE (http://resource.psychencode.org/) and human-specific gene promoter information from Eukaryotic Promoter Database (EPD, https://epd.epfl.ch//index.php) ^{29, 30}. For a given gene, DNMs occurring in its gene body, which includes both exons and introns, brain-specific gene enhancer and gene promoter regions were considered as burdens. For a given gene, we compared the number of DNMs mapped to these regions in SCZ patients with the number of DNMs

mapped to these regions in unaffected siblings, and then assessed the significance of the comparison using 10,000 within-sibship case-control label-swapping permutations. *P* value was calculated as the proportion of permutations with relative risk (RR) as or more extreme than in the observed data.

Developmental expression of DNM-implicated genes

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

Multiple lines of evidence have shown that prenatal maternal infection, malnutrition and stress are risk factors for SCZ ³¹⁻³³. The neurodevelopmental model of SCZ posits that a perturbation in early brain development leads to an altered brain developmental trajectory that is sensitive to molecular changes associated with development and environmental experience, consequently converging on the emergence of SCZ in early adulthood ³⁴. It was hypothesized that DNMs drove dysfunction of genes in early brain development and that this dysfunction confers risks for subsequent SCZ. To determine whether DNM-implicated genes (loss-of-function DNM genes and DNM-burdened genes) were involved in early brain development, human brain developmental expression data from BrainCloud and BrainSpan was evaluated ^{35, 36}. The expression data of BrainCloud consisted of data derived from the prefrontal cortices of 269 individuals ³⁵, whereas the expression data of BrainSpan consisted of 42 brain specimens across 13 developmental states in 8-16 brain structures ³⁶. BrainCloud expression data was examined by comparing the expression of a DNM gene in prenatal stage to the expression in postnatal stage and BrainSpan expression data was evaluated by leveraging the developmental effect scores curated in a previous publication ³⁷. A developmental effect score measures the effect of age on expression per gene per brain structure, with a higher developmental effect score of a gene in a given brain structure indicating a stronger involvement of brain development in that structure. By 10,000 gene label-swapping permutation, P value of a DNM gene for a given brain structure was

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

calculated as the proportion of permutations with developmental effect scores as or more extreme than the observed value. DNM genes were then further evaluated in brain developmental expression data from other species (macaque and mouse) 38, 39. Genetic susceptibilities of DNM-implicated genes in SCZ and SCZ-related traits To determine whether DNM-implicated genes are among the loci found by the genome-wide association study (GWAS) of SCZ or SCZ-related traits, we used GWAS summary statistics from SCZ ¹, ASD ⁴⁰, ADHD ⁴¹, bipolar disorder (BD) ⁴², major depressive disorder (MDD) ⁴³, intelligence 44, educational attainment (EA) 45, cognitive performance (CP) 45, and smoking and drinking ⁴⁶. The criterion for annotating a single nucleotide polymorphism (SNP) to a given gene was that the GWAS SNP is located within 10 kb of the gene boundaries. Co-expression and enrichment analysis To explore the potential functions or pathological pathways affected by DNM-implicated genes, expression data from BrainCloud was leveraged by retrieving genes highly co-expressed with the candidate DNM genes. To identify enrichments in gene ontologic features, biological pathways, diseases and drug targets, WebGestalt was used (http://www.webgestalt.org/) 47. In WebGestalt, genes co-expressed with the candidate DNM gene were input as the target gene set and all genes in the BrainCloud expression data were input as the reference gene set. Enrichments with B-H FDR-corrected P values less than 0.05 were considered significantly enriched. Cell-type specific expression analysis To examine cell-type specific expression of DNM-implicated genes, brain tissue single nucleus RNA-seq (snRNA-seq) data of middle temporal gyrus (MTG), of which the cells have been subtyped from Allen Brain Atlas (https://celltypes.brain-map.org/rnaseq) and single cell expression

data from PsychENCODE were utilized. Single cell expression data from PsychENCODE were merged from multiple brain regions, including frontal cortex, visual cortex and cerebellar hemisphere ⁴⁸. Raw read count data was normalized by log-transformation using R package Seurat ⁴⁹. For a given DNM gene, the dominant cell type(s) with high expression were determined by pair-wise Wilcoxon test.

Results

The goal of our study was to identify DNM disturbed genes, of which the dysfunctions can contribute to the pathogenesis of SCZ. We identified coding DNM-implicated genes and genes carrying more DNM burdens in SCZ patients than their unaffected siblings. These DNM-implicated genes were potentially detrimental and subsequent analyses were performed to explore their pathological effects (Figure 1).

Identification of DNMs and genes implicated by DNMs

To ensure parental unrelatedness and that the children are indeed biological offspring of their parents, kinship analysis was performed for each individual family. For the Taiwan cohort, one family (Family ID: 35-04560) was excluded as the father is within the third degree relative of the mother, one family (Family ID: 35-93405) was excluded as the father was not found to be related to any of the children and one child in one family was excluded as he was found to be unrelated to his parents (Individual ID: 35-02497-01) (Supplementary Table S1). Three children from Shanghai cohort were excluded as they were unrelated to their respective parents (Individual IDs: CHG000225, CHG000236 and CHG000246) (Supplementary Table S1). A total of 21 families were retained for analyses. For detailed information of the families recruited and the individuals

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

in each family in the Taiwan and Shanghai cohorts and the families or individuals excluded due to unrelatedness, please refer to Supplementary Table S1. In this study, 70.71 ± 6.83 de novo point mutations and 6.31 ± 3.64 de novo indel mutations with high confidence per individual were identified. The observed de novo point mutation rate of 1.145×10^{-8} was consistent with the neutral expectation of 1.140×10^{-8} (P = 0.95, two-sided exact binomial test) 23 . The observed de novo indel mutation rate of 1.022×10^{-9} was consistent with the neutral expectation of 1.420×10^{-9} (P = 0.500, two-sided exact binomial test) ²³. All DNMs were checked visually by Integrative Genomics Viewer (IGV). Overall, the DNMs occurred in non-coding regions predominantly in intergenic regions (Supplementary Figure S4). No obvious difference was observed between unaffected siblings and SCZ patients with regards to the distributions of DNM locations relative to genes (Supplementary Figure S4). No obvious differences were observed between unaffected siblings and SCZ patients with regards to the percentages of DNMs occurring in exons (unaffected siblings: 29.85% versus SCZ patients: 30.29%) and introns (unaffected siblings: 1.53% versus SCZ patients: 2.03%). The nonsynonymous-to-synonymous ratio in SCZ patients was not found to be different from the ratio in unaffected siblings ⁵⁰, which might be attributed to the limited sample size. Two nonsense loss-of-function DNMs implicating GJC1 and HIST1H2AD respectively were identified in SCZ patients (Table 1 and Supplementary Table S4). The two loss-of-function DNMs were visually verified by IGV (Supplementary Figure S5 and S6) and then were confirmed by Sanger sequencing (Supplementary Figure S7 and S8). To examine whether the occurrence rates of nonsense loss-of-function DNMs in GJC1 and HIST1H2AD in SCZ patients were higher than expected by chance, we compared the nonsense mutation probabilities of GJC1 and HIST1H2AD to those of all genes calculated in Samocha et al. 51. Nonsense DNMs were not

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

prone to occur in DNA regions of GJC1 and HIST1H2AD (Supplementary Figure S9). No lossof-function DNMs were identified in unaffected siblings on the whole genome scale (Supplementary Table S3). Except for the two nonsense loss-of-function DNMs, we also investigated other DNMs in coding regions to find damaging DNMs because DNMs occurring in coding regions may change protein structures physically (Figure 1 and Supplementary Table S3). A detailed list of these DNMs are shown in Supplementary Table S4. To identify genes implicated by these protein-coding DNMs, denovolyzeR was used. Due to the relatively small sample size of this study, Bonferroni correction was used to reduce the false discovery rate. Only GJC1 and HIST1H2AD carrying nonsense DNMs were significantly identified to be implicated by DNMs (Supplementary Table S5). We applied another background mutation rate-based model, referred to as the chimpanzeehuman divergence model, which also showed GJC1 and HIST1H2AD were significantly implicated by the nonsense DNMs (P value = 1.56×10^{-5} for GJC1 and P value = 1.82×10^{-5} for HIST1H2AD) ⁵². Of note, the GJC1 nonsense DNM was predicted to be extremely close to the most severe 0.1% of mutations by combined annotation dependent depletion (CADD) (Supplementary Table S4; mutations with CADD phred-like scores greater than or equal to 30 is the most severe 0.1% of mutations) ⁵³. Moreover, *GJC1* falls into the haploinsufficient category with a high probability of loss-of-function intolerance (pLI) of 0.94, therefore is extremely intolerant of loss-of-function variation ⁵⁴. To investigate whether GJC1 and HIST1H2AD were also implicated by rare variants as DNMs in SCZ, we analyzed SCZ Swedish case-control cohort comprised of 4969 SCZ patients and 6245 controls. Rare variants in the exons of *GJC1* were significantly associated to SCZ (Table 2). Identification of genes burdened with DNMs in SCZ patients

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

Previous studies have shown that 99% of the DNMs occurred in non-coding regions ¹⁰. DNMs occurring in regulatory regions can potentially disturb the bindings of transcriptional factors and thus influence gene expression. If a gene or regulatory regions of the gene carry more DNMs in SCZ patients than their unaffected siblings, this gene may have a role in disease predisposition. Based on this assumption, for a given gene, we compared the number of DNMs that occurred in brain-specific enhancer, promoter and gene body in SCZ patients to the number of DNMs in unaffected siblings by within-sibship case-control label-swapping permutation. Before calculation, to reduce the falsely identified genes by chance, we excluded genes with low total DNM counts in both SCZ patients and unaffected siblings (≤ 3). Due to the relatively small sample size, Bonferroni correction was used to reduce the false discovery rate. Ten genes, DPYSL2, NBPF1, SDK1, ZNF595, ZNF718, GCNT2, SNX9, AACS, KCNQ1 and MSI2, were identified to carry more DNMs in SCZ patients than their unaffected siblings. Multiple DNMs implicated enhancers for *DPYSL2*, *NBPF1*, *SNX9* and *MSI2* (Supplementary Table S6), suggesting the dysregulation of these genes may predispose an individual to SCZ. One single enhancer can regulate the expression of multiple genes. Therefore, single DNM implicating an individual enhancer can disturb the expression of multiple genes. We leveraged transcription factor (TF)-enhancer-target gene linkage data from PsychENCODE to establish the gene regulatory network disturbed by the DNMs implicating the enhancers identified by DNM burden test (Figure 2). For detailed list of the DNMs found in the ten genes reported here, please refer to Supplementary Table S6. Interestingly, no DNM occurred in promoters of the ten genes.

DNMs occurred in genes involving in early brain development

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

In the following analyses, coding DNM-implicated genes (GJC1 and HIST1H2AD, Supplementary Table S5) and DNM-burdened genes (Table 3) were as assumed to be detrimental DNM genes to explore their potential functions that might be related to SCZ. Early neurodevelopmental events have been implicated in the pathogenesis of SCZ ³⁴. Genes implicated in SCZ function in processes important to fetal brain development ^{50, 55}. To determine whether the detrimental DNM genes, including GJC1 and HIST1H2AD implicated by nonsense mutations (Supplementary Table S5) and genes carrying more DNMs in SCZ patients (Table 3), were involved in brain development, we leveraged the developmental expression data of prefrontal cortices (PFC), one of the most highly implicated brain regions in SCZ, from BrainCloud. Nine of the 13 detrimental DNM genes, including the two loss-of-function DNMimplicated genes GJC1 and HIST1H2AD, and seven DNM-burdened genes DPYSL2, NBPF1, SDK1, ZNF595, ZNF718, KCNQ1 and SNX9, showed biased higher expression in prenatal stage compared to that of the expression in postnatal stage (Figure 3). The large proportion of 9/12 potentially detrimental DNM genes with higher expression in prefrontal cortices was more than expected by chance (Supplementary Figure S10, P = 0.05, hypergeometric test). We next sought to examine whether the involvements of detrimental DNM genes in PFC development were preserved in other brain regions. The genes with available developmental data in BrainSpan were analyzed. It was found that GJC1, SDK1 and GCNT2 were still involved in the developments of other brain regions (Supplementary Figure S11). To examine whether the involvements of detrimental DNM genes in human brain development were conserved across species, we first queried the brain developmental expression data of macaque, a primate species evolutionarily close to *Homo sapiens*. Only DNM genes with expression data of macaque were analyzed. GJC1, HIST1H2AD, DPYSL2, SDK1 and MSI2 showed higher expression in prenatal stage than the

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

expression in postnatal stage (Supplementary Figure S12). We then queried the brain developmental expression data of mouse. Since the developmental data of mouse were limited in postnatal stage, we applied linear regression to examine the change of DNM gene expression level with time. The expression levels of GJC1, DPYSL2, SDK1 and AACS significantly decreased with time (Supplementary Figure 13), which implied their involvements in prenatal neurodevelopment of mouse. Specifically for GJC1, Leung et al. showed that GJC1 displayed high expression in embryonic stage followed by a massive postnatal decrease in the rat midbrainfloor, where dopaminergic neurons were mostly populated ⁵⁶. Common variants in detrimental DNM genes may influence risks of SCZ-associated traits To determine whether the detrimental DNM genes are involved more broadly in SCZ, we asked whether common variants present in the DNM genes confer risk for SCZ and SCZ-associated traits. We extracted all SNPs that occur within 10 kb of the DNM genes. For a given trait, the SNP with the minimum P value mapped to the gene was used to represent the gene risk on the trait. Genes with minimum SNP P values less than the suggestive threshold of 1×10^{-5} were considered as risk genes for the trait. We found that the DNM genes influence risk for SCZassociated traits, including intelligence, educational attainment, cognitive performance, smoking and drinking primarily (Supplementary Table 7). Of note, GJC1, HIST1H2AD and SDK1 confer risks for multiple SCZ-associated traits with SNPs passed the genome-wide significance threshold of 5×10^{-8} . GJC1 co-expressed with multiple potassium channel genes and is a potentially target for SCZ Next, we focused on the loss-of-function DNM gene GJC1, a member of the connexin gene family, which showed strong evidence of SCZ susceptibility (Supplementary Table S8). DNMs

in other brain-associated connexin genes were also found in psychiatric patients (Supplementary Table S9). GJC1 showed higher expression in prenatal stage than the expression in postnatal stage in PFC and multiple other brain regions, and its involvement in early brain development was conserved across species (Figures 3; Supplementary Figures S11, S12 and S13). Moreover, common variants present in GJC1 confer risks for intelligence, educational attainment, cognitive performance and alcohol abuse, which were associated with SCZ (Supplementary Table S7) ⁵⁷⁻⁶⁰. To explore the pathogenic effects of GJC1, we first sought to identify the genes that might be impacted by the dysfunction of GJC1. We performed co-expression analysis with Pearson correlation coefficient greater than 0.8 or less than -0.8 in PFC to identify these genes (Figure 4A and supplementary Table S10). Then we leveraged the genes co-expressed with GJC1 to perform enrichment analysis to identify functions or pathways involved by GJC1. Interestingly, the genes co-expressed with GJC1 were enriched in SCZ, SCZ drug zuclopenthixol and SCZ-associated functions or pathways, including potassium ion transport (Figure 4B and Supplementary Table S11). Of note, multiple potassium ion channel genes were negatively co-expressed with GJC1 (Figure 4A), suggesting their dysfunctions may be subsequent to the dysfunction of GJC1. To determine whether the expression of GJC1 was specific to a certain cell type, we performed cell type specific analysis of GJC1 expression. GJC1 was predominantly expressed in glutamatergic excitatory neurons (Figure 4C and 4D, refer to Supplementary Tables S12 and S13 for pair-wise P values among different cell types derived from Wilcoxon rank sum test). This should be interesting as glutamatergic dysfunction has long been implicated in SCZ ⁶¹.

Discussion

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

In this study, we used two matched SCZ-sibling family cohorts of Han Chinese origin to investigate DNMs and DNM-implicated genes in SCZ. By integrating this information with publicly available data, including brain developmental expression profiles and summary GWAS statistics, we identified DNM-implicated genes that were involved in fetal neurodevelopment. These genes may confer risks for SCZ or SCZ-associated traits, and are potential drug therapy targets for SCZ. Connexin 45 (Cx45) encoded by GJC1 is a component of the gap junction channel. It is one of the two connexin genes expressed predominantly in neurons ⁶². Our analyses showed that *GJC1* was expressed highly in prenatal stage as compared to that in postnatal stage and was expressed predominantly in glutamatergic excitatory neurons in the human brain (Figure 4C and 4D). For the nonsense mutation identified in our study, its occurrence might trigger the activation of surveillance pathway nonsense-mediated mRNA decay (NMD), which reduces aberrant proteins to be formed ⁶³. The reduction of *GJC1* may perturb the co-expressed genes and thus influence the potassium ion transport and axon/dendrite formations, especially in early neurodevelopment (Figure 4A and 4B). Krüger et al. reported Cx45-deficient embryos exhibited striking abnormalities in vascular development and died between embryonic day 9.5 and 10.5 ⁶⁴. Kumai et al. reported that Cx45-deficient embryos displayed an endocardial cushion defect in early cardiogenesis and died of heart failure at around embryonic day 9 65. Nishii et al. showed that mice lacking Cx45 conditionally in cardiac myocytes displayed embryonic lethality and the requirement of Cx45 for developing cardiac myocytes ⁶⁶. These studies indicate the critical role of Cx45 in embryonic development. Our results showed that GJC1 displayed biased high expression across multiple brain regions in prenatal stage, suggesting it is required for neurodevelopment. The high expression of GJC1 in prenatal/early stage in other species

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

indicated its involvement in development is phylogenetically conserved. The dysfunction or lossof-function can cause lethal effects, thereby such mutation would be eliminated by natural selection in evolution. Interestingly, all potassium ion channel genes were negatively coexpressed with GJC1. Therefore, the reduction of GJC1 indicates an increase or overactivity of potassium channels. Miyake et al. reported overexpression of Ether-a`-go-go potassium channel gene KCNH3 in the forebrain can impair the performances of working memory, reference memory and attention ⁶⁷. Ghelardini *et al.* reported that administrations of potassium channel openers bring out amnesic effect which can be reversed by potassium channel blockers ⁶⁸. This evidence suggested that the cognitive or memory deficits in this case were caused by the increased expression of potassium channel genes due to the reduction of GJC1 activity (Figure 5). The various connexins of gap junctions may be capable of differentiating between the operation qualities of the cognate synapses defined by the neurotransmitter types ⁶⁹. Mitterauer et al. raised a hypothesis that if the function of glial gap junction proteins is lost, the brain is incapable of distinguishing between the same and different qualities of information processing and thus cause severe cognitive impairments in SCZ ⁶⁹. Our findings support these hypotheses. Overall, the lossof-function of Cx45 may be a driver of pathogenesis for some SCZ cases. HIST1H2AD, the other nonsense DNM gene close to HLA locus, encodes the member D in the histone cluster 1 H2A family. Studies have demonstrated that several SCZ candidate genes are especially susceptible to changes in transcriptional activity as a result of histone modification ⁷⁰, ⁷¹. Therefore, a deficit in the histone itself can implicate multiple SCZ candidate genes. Moreover, epigenetic regulation effects of histone deacetylase inhibitors were potentially suggested to treat SCZ ⁷², which implies the fundamental role of histone in the pathology of SCZ.

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

Gene level DNM burden test identified a list of genes carrying more DNMs in SCZ patients than their unaffected siblings. In the literature, there were experimental or clinical evidences demonstrating their potential association with SCZ. Luan et al. reported SNPs in MSI2 are strongly associated with SCZ in the Chinese population ⁷³. In the GWAS of PGC, the SNPs in MSI2 were also associated with SCZ (Supplementary Table 7). Another DNM-burdened genes, DPYSL2, is a member of the collapsin response mediator protein (CRMP) family. CRMP forms homo- and hetero-tetramers and facilitates neuron guidance, growth and polarity. It also plays a role in synaptic signaling through interactions with calcium channels. Lee et al. revealed that DPYSL2 was downregulated in the PFC and hippocampus of prenatally stressed (PNS) adult rats that underperformed in behavioral tests ⁷⁴. Bruce *et al.* conducted potassium channel-targeted SNP association analyses with SCZ and SCZ-associated phenotypes. rs8234 in KCNQ1, a DNMburdened gene in our study, was associated to processing speed ⁷⁵. Geschwind *et al.* found that patients with voltage-gated potassium channel complex antibody (VGKCC-Abs) had particular impairment in memory and executive functions when they evaluated cognitive function and imaging data in patients with VGKCC-Abs associated encephalopathy ⁷⁶. Interestingly, the impaired brain functions coincide with the two most implicated brain regions in SCZ, dorsolateral prefrontal cortex and the hippocampus ⁷⁷. This evidence demonstrated the efficacy of our DNM burden test by incorporating enhancer and promoter regions into consideration. It also indicated DNMs contributing to the genesis of disease are not limited in coding regions, underling the value of WGS. Except for HIST1H2AD, common variants in these identified DNM genes were not strongly associated to psychiatric diseases. However, a few of them, GJC1, HIST1H2AD and SDK1, were strongly associated to SCZ-associated traits, including intelligence, educational attainment,

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

smoking and drinking. It suggested the significance of these DNM genes in neurodevelopment and that the lethal mutations occurred in these genes were eliminated by marked reduction of fecundity in psychiatric patients. The results should be interpreted with caution because of limited samples in the pilot study. A few parents with other mental illness from the Taiwan cohort may complicate the interpretation of the DNMs if the mental illness shares certain genetic liability with SCZ. Nevertheless, the association of the nonsense DNM gene GJC1 with SCZ is deemed reliable: First, the association of GJC1 with SCZ is supported by the analyses of rare variants of an independent exome sequencing dataset where SCZ patients have more rare variants in the gene than controls²⁷. Second, with its intolerance of loss-of-function index of pLI = 0.94, the loss-of-function mutation is very likely to have detrimental consequences in the regulation of ion channels which have been implicated in the pathogenesis of SCZ^{78, 79}. To validate our findings, future studies with more and independent Chinese family samples are necessary. In summary, we identified a list of DNM-implicated genes which are involved in prenatal neurodevelopment. Common variants in these DNM-implicated genes had been previously reported to be associated with SCZ and related traits in previous GWASs, which is consistent with our analyses. DNMs implicating the enhancers may contribute to pathogenesis of SCZ by dysregulating the expression of genes. GJC1 is one of these DNM-implicated genes that is primarily expressed in glutamatergic neurons and may be involved in the modulation of ion channel functions, which has also been implicated in SCZ in previous studies ^{78, 79}. Overall, our study provided new evidence that DNMs have a significant role in SCZ. Further study of these DNM-implicated genes with functional analyses could lead to better understanding of the pathology of SCZ.

Acknowledgements

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

This work was supported in part by grants from National Institutes of Health (R01MH101054 to X.C. and R01LM012806 to Z.Z.), the National Natural Science Foundation of China (grant 81421061), the National Key Research and Development Program (2016YFC0906400), Shanghai Key Laboratory of Psychotic Disorders (13dz2260500), Cancer Prevention and Research Institute of Texas (RR180012 to X.J.), and UT Stars award to X.J. The DNA samples of the subjects from Taiwan cohort were obtained through NIMH Genetics Repository. The DNA samples of the subjects from Shanghai cohort were from the Bio-x SCZ Biobank in Shanghai, China. Computational resources from the school of biomedical informatics at The University of Texas Health Science Center at Houston were used in data analysis. The data from the TSLS were collected with funding from grant R01MH59624 from K. S. K. and M. T. The whole genome sequencing of samples from Taiwan cohort were supported by grant from National Institutes of Mental Health (1RO1-MH085560) to M.T. We acknowledge Dr. Hai-Gwo Hwu and Dr. Wei J. Chen for their recruitment of families, collection of clinical data and preprocess of blood samples in Taiwan cohort. We acknowledge the help from Dr. Lukas Simon on single cell analysis and the collection of GWAS summary statistics from Dr. Yulin Dai. We acknowledge the altruism of the participants and their families and support staff at each of the participating sites for their contributions to this study.

Author contributions

S.J. designed the study, performed the analyses, interpreted the results and wrote the manuscript.

D.Z. collected the demographic data and performed whole genome sequencing, data processing, quality control and cleaning from Shanghai cohort. Y.W., P.J., C.W., X.L., G.H., D.C., X.J., T.M. and J.S.W. contributed to data processing, quality control and cleaning. K.S.K. and M.T. contributed to data collection and whole genome sequencing. J.S.W., Y.L. and J.C. conducted Sanger sequencing experiment. T.M. revised the manuscript. L.H., J.C., Z.Z., P.J. and X.C. conceived the project, designed the study, collected the data, interpreted the results and wrote the manuscript.

Conflict of interest

The authors declare that they have no conflict of interest.

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

Figure legends Figure 1. Schematic of genetic data processing, DNM identification and functional analysis in 23 families with schizophrenia patients and matched unaffected siblings. SNV, single nucleotide variant; INDEL, insertion and deletion. Figure 2. Gene regulatory network disturbed by the DNMs implicating the enhancers identified by DNM burden test. Light green arrow nodes are the transcription factors. The yellow round nodes are the enhancers perturbed by the DNMs. The Orange round nodes are the genes. The edge between transcription factor and enhancer represent the transcription factor can bind to the enhancer without the perturbation of DNM. The edge between enhancer and gene represent the enhancer can enhance the expression of the gene without the perturbation of DNM. Red labeled genes were those identified by DNM burden test. Figure 3. Detrimental DNM genes implicated in early brain development in PFC. A, GJC1; B, *HIST1H2AD*; C, *DPYSL2*; D, *NBPF1*; E, *SDK1*; F, *ZNF595*; G, *ZNF718*; H, *KCNQ1*; I, *SNX9*. Black dots represent samples from prenatal stage. Blue dots represent samples from postnatal stage. P values were derived from Wilcoxon rank sum test by comparing gene expression from prenatal stage to postnatal stage. Figure 4. Genes co-expressed with GJC1 were enriched in schizophrenia and schizophrenia-associated pathways and drug. A, GJC1-hubed co-expression network. The nodes of genes positively co-expressed with GJC1 ($r_{pearson} > 0.8$) were labeled in red and the nodes of genes negatively co-expressed with GJC1 ($r_{pearson} < -0.8$) were labeled in blue. The names of potassium channel genes co-expressed with GJC1 were marked in red. B, significantly enriched terms by genes co-expressing with GJC1. C. Cell-type specific expression of GJC1 in

the middle temporal gyrus of human brain from Allen Brain Atlas. D. Cell-type specific expression of GJC1 in mixed brain regions, including the frontal cortex, visual cortex and cerebellum hemisphere, from PsychENCODE. Figure 5. Schematic illustration of possible mechanism of dysfunction of GJC1 leads to **SCZ.** Loss of gap junction formed by connexin 45 blocked the pass of ions and small molecules between brain cells, which caused the state of homeostatic imbalance in cell. Increased potassium channel subsequent to the loss of gap junction leads to cognitive impairment and memory loss in SCZ patients.

References

575

578

582

586

590

596

599

603

606

610

- 576 1. Schizophrenia Working Group of the Psychiatric Genomics C. Biological insights from 108 schizophrenia-associated genetic loci. *Nature* 2014; **511**(7510): 421-427.
- Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N *et al*.
 Schizophrenia risk from complex variation of complement component 4. *Nature* 2016;
 530(7589): 177-183.
- Marshall CR, Howrigan DP, Merico D, Thiruvahindrapuram B, Wu W, Greer DS *et al.*Contribution of copy number variants to schizophrenia from a genome-wide study of
 41,321 subjects. *Nat Genet* 2017; **49**(1): 27-35.
- Iossifov I, O'Roak BJ, Sanders SJ, Ronemus M, Krumm N, Levy D *et al.* The contribution of de novo coding mutations to autism spectrum disorder. *Nature* 2014; **515**(7526): 216-221.
- 591 5. Kim DS, Burt AA, Ranchalis JE, Wilmot B, Smith JD, Patterson KE *et al.* Sequencing of sporadic Attention-Deficit Hyperactivity Disorder (ADHD) identifies novel and potentially pathogenic de novo variants and excludes overlap with genes associated with autism spectrum disorder. *Am J Med Genet B Neuropsychiatr Genet* 2017; **174**(4): 381-389.
- Epi KC. De Novo Mutations in SLC1A2 and CACNA1A Are Important Causes of Epileptic Encephalopathies. *Am J Hum Genet* 2016; **99**(2): 287-298.
- 7. Xu B, Roos JL, Dexheimer P, Boone B, Plummer B, Levy S *et al.* Exome sequencing supports a de novo mutational paradigm for schizophrenia. *Nat Genet* 2011; **43**(9): 864-868.
- 604 8. Girard SL, Gauthier J, Noreau A, Xiong L, Zhou S, Jouan L *et al.* Increased exonic de novo mutation rate in individuals with schizophrenia. *Nat Genet* 2011; **43**(9): 860-863.
- Fromer M, Pocklington AJ, Kavanagh DH, Williams HJ, Dwyer S, Gormley P *et al.* De novo mutations in schizophrenia implicate synaptic networks. *Nature* 2014; **506**(7487): 179-184.
- Francioli LC, Polak PP, Koren A, Menelaou A, Chun S, Renkens I *et al.* Genome-wide patterns and properties of de novo mutations in humans. *Nat Genet* 2015; **47**(7): 822-826.

Wang GS, Cooper TA. Splicing in disease: disruption of the splicing code and the decoding machinery. *Nat Rev Genet* 2007; **8**(10): 749-761.

616

620

624

628

632

635

639

643

646

- Takata A, Matsumoto N, Kato T. Genome-wide identification of splicing QTLs in the human brain and their enrichment among schizophrenia-associated loci. *Nat Commun* 2017; **8:** 14519.
- Takata A, Ionita-Laza I, Gogos JA, Xu B, Karayiorgou M. De Novo Synonymous Mutations in Regulatory Elements Contribute to the Genetic Etiology of Autism and Schizophrenia. *Neuron* 2016; **89**(5): 940-947.
- Hwu HG, Faraone SV, Liu CM, Chen WJ, Liu SK, Shieh MH *et al.* Taiwan schizophrenia linkage study: the field study. *Am J Med Genet B Neuropsychiatr Genet* 2005; **134B**(1): 30-36.
- Faraone SV, Hwu HG, Liu CM, Chen WJ, Tsuang MM, Liu SK *et al.* Genome scan of Han Chinese schizophrenia families from Taiwan: confirmation of linkage to 10q22.3. *Am J Psychiatry* 2006; **163**(10): 1760-1766.
- 633 16. Chen WJ, Hsiao CK, Hsiao LL, Hwu HG. Performance of the Continuous Performance 634 Test among community samples. *Schizophr Bull* 1998; **24**(1): 163-174.
- Chen J, Wu JS, Mize T, Moreno M, Hamid M, Servin F *et al.* A Frameshift Variant in the
 CHST9 Gene Identified by Family-Based Whole Genome Sequencing Is Associated with
 Schizophrenia in Chinese Population. *Sci Rep* 2019; 9(1): 12717.
- Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine A

 et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best
 practices pipeline. Curr Protoc Bioinformatics 2013; 43: 11 10 11-33.
- Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 2009; **25**(14): 1754-1760.
- Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D *et al.* PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 2007; **81**(3): 559-575.
- Francioli LC, Cretu-Stancu M, Garimella KV, Fromer M, Kloosterman WP, Genome of the Netherlands c *et al.* A framework for the detection of de novo mutations in familybased sequencing data. *Eur J Hum Genet* 2017; **25**(2): 227-233.

Wei Q, Zhan X, Zhong X, Liu Y, Han Y, Chen W *et al.* A Bayesian framework for de novo mutation calling in parents-offspring trios. *Bioinformatics* 2015; 31(9): 1375-1381.

Ramu A, Noordam MJ, Schwartz RS, Wuster A, Hurles ME, Cartwright RA *et al.*DeNovoGear: de novo indel and point mutation discovery and phasing. *Nat Methods*2013; **10**(10): 985-987.

657

661

664

668

671

675

679

682

686

690

- Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res* 2010; **38**(16): e164.
- Untergasser A, Nijveen H, Rao X, Bisseling T, Geurts R, Leunissen JA. Primer3Plus, an enhanced web interface to Primer3. *Nucleic Acids Res* 2007; **35**(Web Server issue): W71-74.
- Ware JS, Samocha KE, Homsy J, Daly MJ. Interpreting de novo Variation in Human Disease Using denovolyzeR. *Curr Protoc Hum Genet* 2015; **87:** 7 25 21-15.
- Singh T, Kurki MI, Curtis D, Purcell SM, Crooks L, McRae J et al. Rare loss-of-function variants in SETD1A are associated with schizophrenia and developmental disorders. Nat Neurosci 2016; 19(4): 571-577.
- Ionita-Laza I, Lee S, Makarov V, Buxbaum JD, Lin X. Sequence kernel association tests for the combined effect of rare and common variants. *Am J Hum Genet* 2013; **92**(6): 841-853.
- Wang D, Liu S, Warrell J, Won H, Shi X, Navarro FCP *et al.* Comprehensive functional genomic resource and integrative model for the human brain. *Science* 2018; **362**(6420).
- Dreos R, Ambrosini G, Perier RC, Bucher P. The Eukaryotic Promoter Database: expansion of EPDnew and new promoter analysis tools. *Nucleic Acids Res* 2015; **43**(Database issue): D92-96.
- Khandaker GM, Zimbron J, Lewis G, Jones PB. Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies. *Psychol Med* 2013; **43**(2): 239-257.
- Susser E, St Clair D, He L. Latent effects of prenatal malnutrition on adult health: the example of schizophrenia. *Ann N Y Acad Sci* 2008; **1136:** 185-192.

- Khashan AS, Abel KM, McNamee R, Pedersen MG, Webb RT, Baker PN *et al.* Higher risk of offspring schizophrenia following antenatal maternal exposure to severe adverse life events. *Arch Gen Psychiatry* 2008; **65**(2): 146-152.
- Birnbaum R, Weinberger DR. Genetic insights into the neurodevelopmental origins of schizophrenia. *Nat Rev Neurosci* 2017; **18**(12): 727-740.

700

704

707

711

715

718

723

727

- 701 35. Colantuoni C, Lipska BK, Ye T, Hyde TM, Tao R, Leek JT *et al.* Temporal dynamics and genetic control of transcription in the human prefrontal cortex. *Nature* 2011; 478(7370): 519-523.
- 705 36. Miller JA, Ding SL, Sunkin SM, Smith KA, Ng L, Szafer A *et al.* Transcriptional landscape of the prenatal human brain. *Nature* 2014; **508**(7495): 199-206.
- 708 37. Grote S, Prufer K, Kelso J, Dannemann M. ABAEnrichment: an R package to test for gene set expression enrichment in the adult and developing human brain. *Bioinformatics* 2016; **32**(20): 3201-3203.
- 712 38. Fertuzinhos S, Li M, Kawasawa YI, Ivic V, Franjic D, Singh D *et al.* Laminar and temporal expression dynamics of coding and noncoding RNAs in the mouse neocortex. *Cell Rep* 2014; **6**(5): 938-950.
- Bakken TE, Miller JA, Ding SL, Sunkin SM, Smith KA, Ng L *et al.* A comprehensive transcriptional map of primate brain development. *Nature* 2016; **535**(7612): 367-375.
- Autism Spectrum Disorders Working Group of The Psychiatric Genomics C. Metaanalysis of GWAS of over 16,000 individuals with autism spectrum disorder highlights a novel locus at 10q24.32 and a significant overlap with schizophrenia. *Mol Autism* 2017; 8: 21.
- 724 41. Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E *et al.* Discovery of 725 the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. *Nat* 726 *Genet* 2019; **51**(1): 63-75.
- Stahl EA, Breen G, Forstner AJ, McQuillin A, Ripke S, Trubetskoy V *et al.* Genomewide association study identifies 30 loci associated with bipolar disorder. *Nat Genet* 2019;
 51(5): 793-803.
- Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A *et al.*Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. *Nat Genet* 2018; **50**(5): 668-681.

Savage JE, Jansen PR, Stringer S, Watanabe K, Bryois J, de Leeuw CA *et al.* Genome-wide association meta-analysis in 269,867 individuals identifies new genetic and functional links to intelligence. *Nat Genet* 2018; **50**(7): 912-919.

735

739

743

747

751

755

759

763

767

771

- Lee JJ, Wedow R, Okbay A, Kong E, Maghzian O, Zacher M *et al.* Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. *Nat Genet* 2018; **50**(8): 1112-1121.
- Liu M, Jiang Y, Wedow R, Li Y, Brazel DM, Chen F *et al.* Association studies of up to
 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use. *Nat Genet* 2019; **51**(2): 237-244.
- Wang J, Vasaikar S, Shi Z, Greer M, Zhang B. WebGestalt 2017: a more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit. *Nucleic Acids Res* 2017; 45(W1): W130-W137.
- Lake BB, Chen S, Sos BC, Fan J, Kaeser GE, Yung YC *et al.* Integrative single-cell
 analysis of transcriptional and epigenetic states in the human adult brain. *Nat Biotechnol* 2018; 36(1): 70-80.
- 49. Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell
 transcriptomic data across different conditions, technologies, and species. *Nat Biotechnol* 2018; 36(5): 411-420.
- Xu B, Ionita-Laza I, Roos JL, Boone B, Woodrick S, Sun Y *et al.* De novo gene
 mutations highlight patterns of genetic and neural complexity in schizophrenia. *Nat Genet* 2012; 44(12): 1365-1369.
- 51. Samocha KE, Robinson EB, Sanders SJ, Stevens C, Sabo A, McGrath LM *et al.* A framework for the interpretation of de novo mutation in human disease. *Nat Genet* 2014; **46**(9): 944-950.
- O'Roak BJ, Vives L, Fu W, Egertson JD, Stanaway IB, Phelps IG *et al.* Multiplex
 targeted sequencing identifies recurrently mutated genes in autism spectrum disorders.
 Science 2012; 338(6114): 1619-1622.
- Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general
 framework for estimating the relative pathogenicity of human genetic variants. *Nat Genet* 2014; 46(3): 310-315.

- Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T *et al.* Analysis of protein-coding genetic variation in 60,706 humans. *Nature* 2016; **536**(7616): 285-291.
- Gilman SR, Chang J, Xu B, Bawa TS, Gogos JA, Karayiorgou M *et al.* Diverse types of genetic variation converge on functional gene networks involved in schizophrenia. *Nat Neurosci* 2012; **15**(12): 1723-1728.
- 56. Leung DS, Unsicker K, Reuss B. Expression and developmental regulation of gap junction connexins cx26, cx32, cx43 and cx45 in the rat midbrain-floor. *Int J Dev Neurosci* 2002; **20**(1): 63-75.

782

786

790

794

797

801

804

806

809

- Aukes MF, Alizadeh BZ, Sitskoorn MM, Kemner C, Ophoff RA, Kahn RS. Genetic
 overlap among intelligence and other candidate endophenotypes for schizophrenia. *Biol Psychiatry* 2009; 65(6): 527-534.
- Le Hellard S, Wang Y, Witoelar A, Zuber V, Bettella F, Hugdahl K *et al.* Identification of Gene Loci That Overlap Between Schizophrenia and Educational Attainment.
 Schizophr Bull 2017; 43(3): 654-664.
- 59. Liddle PF. Schizophrenic syndromes, cognitive performance and neurological dysfunction. *Psychol Med* 1987; **17**(1): 49-57.
- 798 60. Nielsen SM, Toftdahl NG, Nordentoft M, Hjorthoj C. Association between alcohol, cannabis, and other illicit substance abuse and risk of developing schizophrenia: a nationwide population based register study. *Psychol Med* 2017; **47**(9): 1668-1677.
- Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. *Arch Gen Psychiatry* 1995; **52**(12): 998-1007.
- Yamasaki RJC, Neuroimmunology E. Connexins in health and disease. 2018; **9:** 30-36.
- Hug N, Longman D, Caceres JF. Mechanism and regulation of the nonsense-mediated decay pathway. *Nucleic Acids Res* 2016; **44**(4): 1483-1495.
- Kruger O, Plum A, Kim JS, Winterhager E, Maxeiner S, Hallas G *et al.* Defective vascular development in connexin 45-deficient mice. *Development* 2000; **127**(19): 4179-4193.
- Kumai M, Nishii K, Nakamura K, Takeda N, Suzuki M, Shibata Y. Loss of connexin45 causes a cushion defect in early cardiogenesis. *Development* 2000; **127**(16): 3501-3512.

816
817 66. Nishii K, Kumai M, Egashira K, Miwa T, Hashizume K, Miyano Y *et al.* Mice lacking connexin45 conditionally in cardiac myocytes display embryonic lethality similar to that of germline knockout mice without endocardial cushion defect. *Cell Commun Adhes* 2003; **10**(4-6): 365-369.

Miyake A, Takahashi S, Nakamura Y, Inamura K, Matsumoto S, Mochizuki S *et al.*Disruption of the ether-a-go-go K+ channel gene BEC1/KCNH3 enhances cognitive function. *J Neurosci* 2009; **29**(46): 14637-14645.

821

825

828

831

834

838

842

845

849

- 68. Ghelardini C, Galeotti N, Bartolini A. Influence of potassium channel modulators on cognitive processes in mice. *Br J Pharmacol* 1998; **123**(6): 1079-1084.
- Mitterauer B. Loss of function of glial gap junctions may cause severe cognitive impairments in schizophrenia. *Med Hypotheses* 2009; **73**(3): 393-397.
- Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. *Nat Rev Neurosci* 2005; **6**(4): 312-324.
- Guidotti A, Auta J, Davis JM, Dong E, Grayson DR, Veldic M *et al.* GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. *Psychopharmacology (Berl)* 2005; **180**(2): 191-205.
- Hasan A, Mitchell A, Schneider A, Halene T, Akbarian S. Epigenetic dysregulation in schizophrenia: molecular and clinical aspects of histone deacetylase inhibitors. *Eur Arch Psychiatry Clin Neurosci* 2013; **263**(4): 273-284.
- Luan Z, Lu T, Ruan Y, Yue W, Zhang D. The Human MSI2 Gene is Associated with Schizophrenia in the Chinese Han Population. *Neurosci Bull* 2016; **32**(3): 239-245.
- Lee H, Joo J, Nah SS, Kim JW, Kim HK, Kwon JT *et al.* Changes in Dpysl2 expression are associated with prenatally stressed rat offspring and susceptibility to schizophrenia in humans. *Int J Mol Med* 2015; **35**(6): 1574-1586.
- 850 75. Bruce HA, Kochunov P, Paciga SA, Hyde CL, Chen X, Xie Z *et al.* Potassium channel gene associations with joint processing speed and white matter impairments in schizophrenia. *Genes Brain Behav* 2017; **16**(5): 515-521.
- Geschwind M, Gelfand J, Irani S, Neuhaus J, Forner S, Bettcher B. Neuropsychological Profiles Of Voltage-Gated Potassium Channel Complex And Other Autoimmune Encephalopathies; More Than Memory Impairment (S18. 005). AAN Enterprises 2014.

857 858 77. Meyer-Lindenberg AS, Olsen RK, Kohn PD, Brown T, Egan MF, Weinberger DR et al. 859 Regionally specific disturbance of dorsolateral prefrontal-hippocampal functional 860 connectivity in schizophrenia. Arch Gen Psychiatry 2005; **62**(4): 379-386. 861 78. Peltola MA, Kuja-Panula J, Liuhanen J, Voikar V, Piepponen P, Hiekkalinna T et al. 862 AMIGO-Kv2.1 Potassium Channel Complex Is Associated With Schizophrenia-Related 863 Phenotypes. *Schizophr Bull* 2016; **42**(1): 191-201. 864 865 79. Pers TH, Timshel P, Ripke S, Lent S, Sullivan PF, O'Donovan MC et al. Comprehensive 866 867 analysis of schizophrenia-associated loci highlights ion channel pathways and biologically plausible candidate causal genes. Hum Mol Genet 2016; 25(6): 1247-1254. 868 869 870

Table 1. Loss-of-function DNMs identified in schizophrenia patients

	CI a	Position		Reference	26	Mutation	Amino acid
Individual ID	Chr ^a	(hg19)	Gene	allele	Mutant allele	type	substitution
35-50505-02	17	42,882,819	GJC1	G	A	Nonsense	p.Q123X
35-06277-01	6	26,199,170	HIST1H2AD	A	ACTTTACCCAG	Nonsense	p.V101Afs×2

873 Chr: chromosome.

871

Table 2. Rare variant association tests for the loss-of-function DNMs identified in schizophrenia patients

Gene	Rare variant frequency in SCZ	Rare variant frequency in control	SKAT P value
GJC1	0.0115	0.0091	5.60×10^{-3}
HIST1H2AD	0.0029	0.0043	6.28×10^{-1}

medRxiv preprint doi: https://doi.org/10.1101/19011007; this version posted January 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.

Table 3. Genes significantly enriched with higher DNM burden in schizophrenia patients than unaffected siblings

Gene symbol	DNM count in unoffected eiblings	DNM count in schizonhyonic notionts	<i>P</i> -value	Bonferroni
	DNM count in unaffected siblings	DNM count in schizophrenia patients	P-value	<i>P</i> -value
DPYSL2	0	6	1 × 10 ⁻⁴	3.4×10^{-3}
NBPF1	0	6	1×10^{-4}	3.4×10^{-3}
SDK1	1	5	1×10^{-4}	3.4×10^{-3}
ZNF595	1	5	1×10^{-4}	3.4×10^{-3}
ZNF718	1	5	1×10^{-4}	3.4×10^{-3}
GCNT2	0	5	1×10^{-4}	3.4×10^{-3}
SNX9	0	5	1×10^{-4}	3.4×10^{-3}
KCNQ1	1	4	1×10^{-4}	3.4×10^{-3}
AACS	1	3	1×10^{-4}	3.4×10^{-3}
MSI2	1	3	1×10^{-4}	3.4×10^{-3}

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5

